Karyopharm Therapeutics Inc. (KPTI) Investor Relations Documents

Karyopharm Therapeutics Inc. (KPTI) investor relations documents from the company's IR site: 3 presentations, 24 press releases; latest deck 2026-05-17. Read in-app with summaries. First-party data.

Karyopharm Corporate Presentation: Karyopharm’s May 2026 corporate presentation details Phase 3 clinical progress for selinexor in myelofibrosis and endometrial cancer.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-10	Press release	Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
2026-07-30	Press release	Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
2026-07-30	Press release	Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
2026-07-01	Press release	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02	Press release	Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking
2026-06-02	Press release	Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Present
2026-06-01	Press release	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01	Press release	Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis F
2026-05-28	Press release	Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
2026-05-17	Presentation	Karyopharm Corporate Presentation
2026-05-14	Earnings deck	https://investors.karyopharm.com/download/Karyopharm-1Q26-Earnings-Presentation.pdf
2026-05-12	Press release	Karyopharm to Participate at Upcoming Investor Conferences
2026-05-07	Press release	Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
2026-04-21	Press release	Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meet
2026-03-24	Earnings deck	Karyopharm Phase 3 SENTRY Topline Results Presentation
2026-01-09	Proxy statement	https://investors.karyopharm.com/image/KPTI+Final+Special+Proxy+Statement+1.9.26.pdf
2025-12-08	Press release	Karyopharm to Participate in Baird's Biotech Discovery Series
2025-12-01	Press release	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Click here to open PDF.
2025-02-19	Press release	Quarterly Results
2024-12-16	Proxy statement	https://investors.karyopharm.com/image/KPTI+Final+Special+Proxy+Statement+12.16.24.pdf
2023-03-29	ESG report	Karyopharm Therapeutics Inc. 2023 ESG Report

KPTI overview · KPTI earnings · KPTI financials · KPTI KPIs · KPTI ownership · KPTI peers · KPTI filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.